Catalyst Brief

← Calendar

Readoutin 134d

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264

Phase 3 primary completion: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer.

Date
Apr 2027
Type
Readout
Indication
Triple Negative Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  1. May2027
  2. Dec2026
  3. Nov2026